Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2014) 3 PP327 | DOI: 10.1530/boneabs.3.PP327

Osteoporosis: treatment

Baseline data of the DEVIDE-study: DEnosumab vs Intravenous Ibandronate: a 2-year retrospective head to head real life study

Karin Amrein1, Christian Muschitz2, Doris Wagner1, Thomas R Pieber1, Heinrich Resch2, Hans Peter Dimai1 & Astrid Fahrleitner-Pammer1


1Department of Endocrinology and Metabolism, Medical University, Graz, Austria; 2The Vinforce Study Group, Medical Department II, St. Vincent Hospital, Vienna, Austria.

Introduction: Effective treatment of postmenopausal osteoporosis (PMO) is frequently compromised by poor adherence to short-term (≤1-monthly) medications. Aim of this study is to investigate the effect of parenteral ibandronate (IBN) compared to denosumab in a cohort of IBN pretreated PMO patients.

Methods: In a retrospective analysis, a total of 808 women were treated with quarterly 3 mg IBN injections for 27+3 months and were regularly monitored at the osteoporosis outpatient clinic at two large academic centers. After denosumab became available, 366 women were switched to receive this therapy due to their own and their physician’s decision, whereas the remaining 442 preferred to stay on IBN. Fracture incidence, BMD, BTM, and adherence/safety of these two parenteral therapies will be analyzed.

Results: Important baseline characteristics are given in the Table 1. There were no differences in any of the parameters investigated including renal and liver function, vitamin D, PTH and bone turnover markers. Laboratory testing, recording of adverse events was done every 6 months, BMD readings, spinal X-ray and fracture assessment were performed at baseline and after 12 and 24 months of ongoing IBN or denosumab therapy.

Table 1 Baseline characteristics
Denosumab (n=366)Ibandronate (n=442)
Age (years)67±768±6
Femoral neck BMD (T-score)−2.1+0.9−2.0+1
Lumbar spine BMD (T-score)−2.8+1.22.7+1.4
Non-vertebral fracture, n (%)26 (7.1%)34 (7.7%)
Vertebral fracture, n (%)69 (18.9%)84 (19%)

Conclusion: The results of this study not only will provide clinicians with insight into persistence with denosumab in comparison to quarterly IBN therapy, but will also compare the effect of denosumab for the first time with a parenteral administered bisphosphonate in respect to safety, changes in BMD as well as fracture incidence and changes in SDI over a time period of 2 years.

Volume 3

European Calcified Tissue Society Congress 2014

Prague, Czech Republic
17 May 2014 - 20 May 2014

European Calcified Tissue Society 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.